News Room

While COVID-19, the disease caused by SARS-CoV-2, has brought much of the world to a standstill, it hasn’t stopped research at NC State. Faculty and the staff at the university have pivoted from their customary research to study COVID-19, using their expertise in battling the pandemic. Their research has covered a large scope, from how the novel coronavirus can be effectively managed and analyzed to how it affects society’s food safety and supply chains.

The United States could be the first country to launch one of the most ambitious vaccine operations in history: distributing and administering up to 600 million doses of a Covid-19 vaccine in just a few months. Massive vaccine campaigns are nothing new -- they have been carried out for decades in the fight against the measles and flu, for example. 

Yuri Levin, professor of Queen’s University Smith School of Business specializing in business analytics and artificial intelligence, takes up the position of Dean of Moscow School of Management SKOLKOVO.

Julie Swann, a professor of industrial and systems engineering at North Carolina State University, who advised the CDC during the H1N1 response, said she believes North Carolina will have all of the necessary logistics in place for mass distribution of a coronavirus vaccine as soon as one if approved.

The U.S. just reached a dark milestone: 10 million reported coronavirus cases. But there is also big news for a potential coronavirus vaccine. On November 9, Pfizer and German drugmaker BioNTech announced that data from their ongoing coronavirus vaccine trial shows the vaccine is more than 90% effective in preventing COVID-19, per the New York Times.